Abstract
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial tumors [1] and the most common type of gastrointestinal cancer following gastric and colorectal cancer [1] [2] [3] [4] . Surgery is the primary treatment option, but patients suffer from high-rates of tumor recurrence or metastasis, resulting in death. The majority of GISTs result from activating mutations in c-KIT and alpha-type platelet-derived growth factor receptor (PDGFRA) [5] . Recent studies have shown that adjuvant therapy with imatinib, a small molecule tyrosine kinase inhibitor, can prolong both survival and time to metastasis following surgery [6] . However, most micro-GISTs (less than 1 cm in diameter) have little malignancy potential despite the presence of KIT or PDGFRA mutations [7] . Furthermore, a 2002 risk assessment for aggressive GISTs showed that tumor growth rates can be affected by numerous factors [8] .
Together, this demonstrates the need for additional prognostic molecular biomarkers to better characterize tumor prognosis and guide treatment strategy.
Secretion of transmitters and hormones is regarded as a hallmark of neuroendocrine cells and tumors. Synaptic-like microvesicle proteins, such as amphiphysin, synaptic vesicle protein, SV2, and synapsin 1, are found in a majority of GISTs [9] . Expression of these proteins enables GISTs to secrete neurotransmitters or hormones, suggesting that GISTs adopt a neuroendocrine phenotype. SLITRK3 is one of the six isoforms of SLIT and neurotropic tyrosine receptor kinase (NTRK)-like family member (Slitrk1-6), which are neuronal transmembrane proteins that control neurite growth [10] . Recently, SLITRK3 has been identified as a post-synaptic adhesion molecule that selectively regulates inhibitory synapse development and is important for normal functional GABAergic synapse development [11] . GABA is a key inhibitory neurotransmitter and mediates synaptic transmission, neural network development [12] , and is involved in digestive diseases such as esophageal reflux and gastric cancer [13] [14] [15] . GISTs may originate from the interstitial cells of Cajal (ICCs), with pacemaker potentials suggesting that mutations in genes involved in synapse or neural development may underlie GIST behavior [9] . In agreement with this, we have previously found that the expression of SLITRK3 was increased in a high-risk group compared to a low-risk group (unpublished data), and Milde et al [16] showed higher SLITRK3 expression levels in lymphoma. The aim of this study was to assess the influence of SLITRK3 on the prognosis of GIST and determine whether SLITRK3 can help improve current risk stratification systems. We hypothesized that upregulation of SLITRK3 is strongly-associated with high recurrence risk and poor prognosis in GIST patients. We tested this by using qRT-PCR and immunohistochemistry on GIST samples and examining the relationship to patient outcome.
MATERIALS AND METHODS

Patients and samples
Formalin-fixed paraffin-embedded (FFPE) tissue Table 1 Risk level access of gastrointestinal stromal tumor sections were collected from GIST patients who underwent surgery at Renji Hospital, Shanghai Jiaotong University School of Medicine, China from 2004 to 2012. The inclusion criteria for this study were as follows: (1) primary GIST cases with definite pathologic diagnosis, as previously described [17] ; (2) all cases received surgical resection; and (3) no reoccurrence or metastasis was detected. The exclusion criteria were: (1) chemotherapy, radiotherapy, or other antitumor therapy before surgery; and (2) incomplete clinicopathologic data. A total of 417 tumor tissue samples, with tumor adjacent normal tissue available for 139, were collected.
All cases were divided into four groups according to the risk table published by the National Institutes of Health (NIH) ( Table 1 ) [8] . Tissue microarray and immunohistochemical staining were performed to access the expression levels of SLITRK3 in these samples. The follow-up data, including survival, reoccurrence, and metastasis as re-examination results, were obtained from outpatient medical records or from patients and their relatives by telephone interview using a follow-up questionnaire.
Additionally, 35 fresh frozen GIST specimens were obtained between 2010 and 2012 from GIST patients who received surgical resection at Renji Hospital, Shanghai Jiaotong University School of Medicine, China. The samples were used for qRT-PCR detection of SLITRK3 expression.
Tissue microarray construction
Tissue microarrays were constructed by Suzhou Xinxin Biotechnology Co., Ltd (Xinxin Biotechnology Co, Suzhou, China). First, 139 GIST tissues with paired tumor adjacent normal tissues were used to construct 3 microarrays, while the other 278 GIST tissues were used to construct another 4 microarrays. Tissue paraffin blocks of GIST samples were stained with hematoxylin-eosin to confirm the diagnoses, and were marked at fixed points with most typical histological characteristics under a microscope. Two 1.6 mm cores per donor block were transferred into a recipient block tissue microarray, with each dot array containing fewer than 160 dots. Three-micron-thick sections were cut from the recipient block and transferred to glass slides with an adhesive tape transfer system for ultraviolet cross linkage.
Immunohistochemistry
The slides were baked at 56 ℃ for 1 h, de-paraffinized in xylene for 20 min, and rehydrated through a graded series of ethanol concentrations (5 min in 100% ethanol followed by 5 min in 70% ethanol). Antigen retrieval was performed in a pressure cooker for 10 min with 0.01 mol/L sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide in methanol at 37 ℃ for 30 min. Next, an SLITRK3 antibody (NBP1-93619, Novus Biologicals, Colorado, United States; concentration: 1:100) was applied to cover the specimens overnight at 4 ℃, which was followed by incubation with a labeled polymer-HRP anti-rabbit secondary antibody (Dako, CA, United States) for 30 min at room temperature. Staining was detected with diaminobenzidine (Thermo, MA, United States) as chromogen and counterstained with hematoxylin prior to coverslipping. The staining intensity and percentage of positive cells were recorded by two pathologists of Renji Hospital (Liu Q and Shen YY) and a consensus score was obtained for each slide. Immunohistochemical scoring was categorized as follows: (1) staining intensity was scored from 0 to 3: 0 for no staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining; (2) staining area was graded into 0-3 levels: 0 for no staining area, 1 for extent to less than 1/3, 3 for more than 2/3, and 2 for in-between; and (3) immunohistochemical classification was based on the sum of intensity and extent score: 0 as negative (-), 1-2 as weakly positive (+), 3-4 as positive (++), and 5-6 as strongly positive (+++). We further ranked the protein level into two classes as (-) or (+) for SLITRK3 low expression while (++) or (+++) was for SLITRK3 high expression.
RNA extraction and RT-PCR conditions
Total RNA was extracted from fresh frozen GIST specimens and GIST cells using RNAiso Plus (Takara, Dalian, China) according to the manufacturer's instructions. RNA quantity and quality were measured by NanoDrop 2000 (NanoDrop, DE, United States). RNA integrity was assessed by standard denaturing agarose gel electrophoresis. Reverse-transcription reactions were performed with Prime Script ® RT
Master Mix (Takara, Dalian, China) according to the manufacturer's instructions. First-strand cDNA was synthesized from 2 μg of total RNA.
Quantitative real-time PCR
All qRT-PCR primer sequences were obtained from the Primer Bank database (http://pga.mgh.harvard.edu/ primerbank/) ( Table 4 Expression levels of SLITRK3 in gastrointestinal stromal tumor and adjacent non-tumor tissues n (%) 
Statistical analysis
For comparisons, one-way analyses of variance, Wilcoxon signed rank test, and chi-squared tests were performed where appropriate. Kaplan-Meier curves were used to visualize biomarker expression, and NIH risk stage with respect to overall survival (OS) and disease-free survival (DFS) data. Univariate and multivariate analyses were based on the Cox proportional hazards regression model. Only those factors statistically significant (P < 0.05) in univariate analysis had access to the next multivariate analyses. Statistical analyses were all performed using SPSS 19.0 software (Chicago, IL, United States). All statistical tests were 2-sided, and P-value differences < 0.05 were considered statistically significant. All statistical analysis was reviewed and confirmed by ZhiGang Zhang.
RESULTS
Patient and tumor characteristics
Detailed clinicopathological data is shown in Table 3 .
Of the 417 paraffin-embedded GIST tissue samples, the predominant cell types were spindle cell (n = 271; 65.0%), epithelioid cell (n = 54; 12.9%), and mixed (n = 92; 22.1%). The maximum tumor diameter detected in GIST patients ranged from 0. 
GIST tumors have high expression of SLITRK3 protein compared with adjacent normal tissues
We performed immunohistochemistry in 139 GIST tissue samples which had both tumor (T) and adjacent non-tumor (N) tissue to determine if expression levels of SLITRK3 differed between tumor and non-tumor tissue. The results showed that SLITRK3 protein was expressed at different levels in different tissue samples and was divided into four classes, as described in materials and methods ( Figure 1A) . Most of the adjacent non-tumor tissues were (-) or (+), while most tumor samples ranged from (+) to (+++) ( Figure  1B and Table 4 signed rank test further confirmed that GIST tumors have a significantly higher expression of SLITRK3 protein than adjacent normal tissue tumor samples (P < 0.001). 
SLITRK3 protein expression level is closely correlated with clinicopathological factors in GIST
SLITRK3 mRNA expression is up-regulated in fresh tumor tissues with higher NIH risk
To further confirm SLITRK3 expression in GIST, the relative expression levels of SLITRK3 mRNAs were analyzed by qRT-PCR in 35 fresh GISTs samples. The relative expression level of SLITRK3 mRNA in the low risk group (n = 13), intermediate risk group (n = 10), and high risk group (n = 12) were 0.002 ± 0.002, 0.008 ± 0.009, and 0.011 ± 0.009, respectively, indicating a gradually increasing trend. SLITRK3 expression in GIST tumor tissues of the intermediate and high risk groups were significantly higher than those of the lowrisk group (P = 0.003 and P = 0.044) (Figure 2 ).
SLITRK3 is a predictor for poor prognosis in GIST patients
The relationship between SLITRK3 expression and overall survival (OS) or disease-free survival (DFS) in GIST patients was investigated. All 398 cases with complete follow-up data were classified into four classes according to SLITRK3 expression levels and calculated according to the Kaplan-Meier method. The 5-year OS rates decreased successively from 100% in (-), 99.0% in (+), 86.7% in (++), and 57.4% in (+++) (Log-Rank-test, P < 0.001) ( Figure 3A) . Meanwhile, the 5-year DFS rates also decreased successively form 91.7% in (-), 78.6% in (+), 71.6% in (++), and 41.8% in (+++) (Log-Rank-test, P < 0.001) ( Figure  3B ). To further investigate whether SLITRK3 can be used as an independent predictor associated with poor prognosis in GIST, univariate and multivariate analysis were performed. Univariate analysis revealed that primary tumor size, mitotic index, NIH stage, and SLITRK3 expression were significantly associated with OS (Table 6 ). Univariate analysis revealed that primary tumor site, primary tumor size, mitotic index, NIH stage, and SLITRK3 expression were significantly associated with DFS (Table 7) . Only those factors with statistically significant relationships with DFS in the univariate analysis were entered in the Cox's proportional-hazard model for multivariate analysis (Table 8 ). The NIH stage is based on primary tumor site, tumor size, and mitotic index, and correlated with each of them strongly, so we developed 3 models for multivariate analysis. Analysis included NIH stage without SLITRK3 expression in model A, SLITRK3 expression instead of NIH stage in model B, and both in model C. In model A, primary tumor site, mitotic index, and NIH stage were statistically significant indicators of poor DFS, and model B showed that SLITRK3 expression is also a significant indicator of poor DFS. Importantly, in model C, SLITRK3 expression (but not NIH stage) was an independent risk factor for GIST recurrence.
SLITRK3 index is helpful to improve the accuracy of NIH risk stratification system
In order to find out whether SLITRK3 can help improve the NIH stage, we further investigated a subgroup of 152 high risk cases. The Kaplan-Meier analysis revealed that the 5-year DFS rate in the SLITRK3 (+++) group was significantly lower than the others (20.3% vs 52.7%, Log-Rank-test, P = 0.018) ( Figure  4) . Furthermore, we found that 71 patients suffered from disease recurrence, mostly with an original high NIH risk rating. Kaplan-Meier curve analysis based on SLITRK3 expression of these patients showed that 1-year and 3-year OS rates in the SLITRK3 (-), (+), (++) group was 83.3% and 61.7%, respectively; the SLITRK3 (+++) group was 58.5% and 9.7%, respectively (Log-Rank-test, P =0.003) ( Figure 5) .
DISCUSSION
In the current study, we examined the correlation between SLITRK3 and GLIST behavior and survival. We found that SLITKR3 was expressed more highly in tumor tissue, correlated well with clinicopathological features, and predicted poor survival in patients. Most Statistically significant (P < 0.01). , group 1 vs group 3) . The SLITRK3 mRNA levels in GIST tumor tissues of the high risk group (group 3) and intermediate risk group (group 2) were significantly higher than those of the low-risk group (group 1) (P = 0.003 and P = 0.044). Table 7 Univariate analysis of factors influencing disease-free survival in 402 patients with gastrointestinal stromal tumor Table 6 Univariate analysis of factors influencing overall survival in 402 patients with gastrointestinal stromal tumor importantly, increasing SLITKR3 expression correlated with decreased overall survival and disease-free survival.
Currently, risk stratification schemes for operable GIST, such as the NIH consensus criteria, modified consensus criteria, and AFIP-Miettinen criteria, all depend on tumor site, tumor size, and mitosis index [8, [18] [19] [20] . Mitosis count is one of the most valuable prognostic factors in GIST, but has limitations and controversial reliability [21] . Observation of mitosis can be subjective, time consuming, and affected by the high power field (HPF) area of the microscope and tissue fixation time. A previous study using 16 different pathologists and different microscopes resulted in a wide counting range from the same sample [22] . Moreover, according to current risk stratification, abrupt changes can occur in estimating risk of recurrence when the tumor size or mitosis index is close to a cutoff value. This is especially important due to the existence of small and mitotically inactive malignant GISTs [1, 23, 24] . Together, these factors suggest that the current risk criteria can be improved significantly. Log-Rank-test, P < 0.001 We found that the clinical measurements in our study, including age, sex, tumor size, and mitoses index, were all similar to previously reported studies [21, [25] [26] [27] . Patients who suffered from disease recurrence or death were mainly from the high-risk group. The 5-year OS and DFS rate of our database were 85.0% and 69.4%, respectively, compared with 72.3% and 70.5%, respectively, from a large multicenter, retrospective analysis of clinical data published in Lancet Oncology 2012 [21] . The better 5-year OS rate of our study might reflect differences in standardized treatment and the use of IM adjuvant therapy.
SLITRK3 is expressed predominantly in neural tissues and has neurite-modulating activity [28] . However, the function of SLITRK3 in solid tumors is poorly studied. In our previous study (unpublished data), the expression of SLITRK3 monotonically increased from the low-risk group to the high-risk group. We found that SLITRK3 was also up-regulated in tumor compared to non-tumor tissue by using immunohistochemistry and qRT-PCR. This finding is in agreement with Milde et al [16] , who demonstrated that SLITRK3 was up-regulated in lymphoma. SLITRK3 expression was also associated with a higher incidence of GI bleeding, a common symptom of GIST and a good indicator for highrisk patients [29, 30] . Furthermore, SLITRK3 expression correlated with NIH risk classification, and the reduced overall survival and disease-free progression suggests that elevated expression of SLITRK3 is a good tumor biomarker candidate, particularly for aggressive GISTs.
The function and mechanism of SLITRK3 protein in the malignant processes of GIST it still unclear, necessitating the need for experiments both in vitro and in vivo. However, it is very likely that there are other potential GIST risk-related genes, as suggested by our previous gene microarray (unpublished data). In agreement with this, the potassium channel tetramerization domain containing protein 10 (KCTD10) has been shown to correlate with GIST prognosis [31] . Future studies and identification of novel prognostic biomarkers will help further stratify risk groups and direct treatment strategies for GIST.
Our detailed analysis showed that SLITRK3 mRNA expression level increased according to NIH risk classification. We found that SLIRTK3 protein level was closely associated with tumor site, tumor size, and mitotic index. As current risk stratification schemes are mainly based on these three features, it is not surprising that up-regulation of SLIRTK3 is strongly associated with a high-risk NIH grade. However, we found that NIH stage was a significant unfavorable factor for OS in univariate analysis, but not multivariate analysis. This suggests that the current NIH criteria is very likely not an optimal prognostic tool. We found that under all circumstances that SLITRK3 expression was a significant predictor of poor prognosis. Therefore, we believe that the combination of SLITRK3 expression and NIH criteria will better stratify post-operative GIST patients. Many patients with operable GIST can be cured by surgery alone and may not benefit from IM adjuvant therapy. Given the expense of IM adjuvant therapy and its associated side effects [32] , an improved selection of patients for adjuvant therapy will be of clinical benefit. Due to the poor prognosis and reduced OS, we strongly suggest that patients with high SLITRK3 expression, especially those who also are in the NIH high-risk groups, receive IM adjuvant therapy and close follow-up management after surgery.
In conclusion, we have identified SLITRK3 as a novel prognostic molecular biomarker that may help guide treatment of GIST.
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